() has moved away from bulk metals like iron and coal, securing an option to acquire up to 50% of an Australian firm with nickel and rare earth exploration potential.
John Peters, executive chairman, said: “This opportunity came along in a sector that we believe has good medium and long-term prospects.”
In a separate statement, the group said it had stopped activity on its Tatu coal project in New Zealand to concentrate on this new project.
Meet Advanced Oncotherapy, VolitionRx, Scancell Holdings Plc, Faron Pharmaceuticals Oy and Highlands Natural Resources Plc at our event,
London, 26 January 2017.
Register here »